Taejoon Pharmaceutical Co., Ltd.
Clinical trials sponsored by Taejoon Pharmaceutical Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Eye drops take aim at dry eye: phase 2 trial puts TJO-087 to the test Results expected Oct 2026 (estimated)
- A daily eye drop might slow childhood nearsightedness. a trial puts it to the test. Results expected Apr 2027 (estimated)
-
A daily eye drop might slow childhood nearsightedness. a trial puts it to the test.
Disease control OngoingThis phase 3 trial tests whether an experimental eye drop called CTO0308 can slow the progression of myopia, or nearsightedness, in children aged 5 to 12. Participants receive either the active drop or a placebo once daily in each eye for 12 months. Researchers measure changes in…
Phase 3 • Sponsor: Taejoon Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Eye drops take aim at dry eye: phase 2 trial puts TJO-087 to the test
Symptom relief OngoingResearchers are testing an experimental eye drop called TJO-087 in adults with dry eye syndrome. The trial enrolls about 90 people who have dry eye symptoms and signs of corneal damage. Participants receive either TJO-087 or a placebo drop for 3 months. The main measure is whethe…
Phase 2 • Sponsor: Taejoon Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC